Navigation Links
Halozyme Reports First Quarter 2013 Financial Results
Date:5/8/2013

ts

10,324,9467,252,768Total revenues

11,833,5407,440,179OPERATING EXPENSES:Cost of product sales

738,97170,761Research and development

22,034,43715,891,109Selling, general and administrative

7,555,9056,618,707Total operating expenses

30,329,31322,580,577OPERATING LOSS

(18,495,773)(15,140,398)Investment and other income

54,98821,217Interest expense

(847,584)-NET LOSS

$ (19,288,369)$ (15,119,181)Basic and diluted net loss per share

$
(0.17)$
(0.14)Shares used in computing basic and diluted

net loss per share

112,416,792107,589,514 Halozyme Therapeutics, Inc.Condensed Consolidated Balance Sheets(Unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

$   39,017,804$   99,501,264Marketable securities, available-for-sale

48,408,220-Accounts receivable, net

10,375,73315,703,087Inventories

2,737,3872,670,696Prepaid expenses and other assets

10,571,33412,752,888Total current assets

111,110,478130,627,935Property and equipment, net

3,975,0523,700,462Prepaid expenses and other assets

1,280,765-Restricted cash

500,000400,000Total Assets

$ 116,866,295$ 134,728,397LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable 

$
2,884,794$
2,271,689Accrued expenses

9,177,5747,783,447Deferred revenue, current portion

6,326,1588,891,017Current portion of long-term debt

1,362,055-Total current liabilities

19,750,58118,946,153Deferred revenue, net of current portion

34,318,48134,954,966Long-term debt, net

28,323,23329,661,680Lease financing obligation

1,450,0001,450,000Deferred rent, net of current portion

906,091861,879Other long term liability

436,849-Stockholders' equity:Common stock

113,143112,709Additional pa
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
2. Halozyme Reports First Quarter 2012 Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozyme Reports Second Quarter 2012 Financial Results
7. Halozyme to Host Third Quarter Financial Results Conference Call
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
(Date:9/2/2014)... 2014 -- ... het ESC CONGRESS 2014 geven inzicht in ... op beroerte in de dagelijkse klinische praktijk ... 12.500 patiënten ingeschreven in de Global Anticoagulant ... innovatief, onafhankelijk initiatief op het gebied van ...
(Date:9/2/2014)... , September 2, 2014 ... Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material (Metal, ... Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by MarketsandMarkets, ... in 2013. It is poised to grow at a ... by 2018. Browse 90 market data ...
Breaking Medicine Technology:Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... Tulsa, OK (PRWEB) September 03, 2014 ... in the sales, installation, and support of Sage 100 ... named a Sage North America Million Dollar Club achiever ... 2013-2014 business year. Sage recognizes CS3 Technology and all ... to the overall success of Sage, its business partners ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... September 03, 2014 Immersion Active ... received a silver medal in the 2014 Content Marketing ... Marketing Awards is the leading awards program for people ... of every medium and strategic purpose. , Immersion ... developed for its client Home Instead Senior Care®. This ...
(Date:9/3/2014)... OR (PRWEB) September 03, 2014 ... the use of appropriate evidence-based health care along ... parties benefit from the expertise of accredited independent ... the health care system. , As a core ... IROs often settle questions of medical necessity. Yet ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Immersion Active Wins Silver for Email Strategy in 2014 Content Marketing Awards 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3
... Healthcare practitioners can increase the number of patients with heart ... cent, helping them to reduce their risk of dying and ... Munk Cardiac Centre. Previous studies, including one by ... a cardiac illness, such as a heart attack, can reduce ...
... Randy Dotinga HealthDay Reporter , MONDAY, Feb. ... Bull, AMP and Rockstar have no health value and ... review finds. The increasingly popular, highly caffeinated drinks ... hyperactivity disorder (ADHD) or other health or emotional problems, ...
... MONDAY, Feb. 14 (HealthDay News) -- Most medical devices recently ... life-threatening or serious safety risks were initially approved for use ... research reveals. The findings call out for an overhaul ... the market in the first place, said the study team, ...
... have a subtype that is characterized by high levels ... tends to be more aggressive than other breast cancer ... is so aggressive could aid in the development of ... researchers, led by Lewis Chodosh, at the University of ...
... , MONDAY, Feb. 14 (HealthDay News) -- ... Afghanistan and Iraq and who were evacuated due to ... military personnel to return to duty, new research shows. ... Department of Defense civilians -- account for about 50 ...
... / MEDai, a leading provider of advanced clinical analytic ... version of Pinpoint Review, its real-time, clinical surveillance system ... set of clinical watch triggers, expanded core measure alerts ... Stay Prediction and Mortality Prediction. "Hospitals are ...
Cached Medicine News:Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 2Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 3Health News:Energy Drinks May Hurt Kids: Study 2Health News:Energy Drinks May Hurt Kids: Study 3Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 2Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 3Health News:Nonmilitary More Likely to Return to War Zone After Psych Condition 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2
... Foot Control allows hands-free operation in nerve ... or 5.0 mA) with SoloStim provides a ... fine control when close to nerve., ... nerve block products, including the clinically proven ...
... ,The Centiva/5 Critical Care Ventilator is your solution ... critical care environment. The Centiva has been designed ... size with high levels of performance. The Centivas ... patients bed and allows you the freedom to ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: